Abstract 190P
Background
Dose-dense (biweekly) paclitaxel/carboplatin(PC) as neoadjuvant Chemotherapy (NCT) for operable breast cancer is feasible and efficient. This study was to analysis the relationship between the molecular biomarkers and tumor response in estrogen receptor(ER) positive breast cancer.
Methods
84 ER-positive breast cancer patients treated with Dose-dense (biweekly) paclitaxel/carboplatin NCT were analyzed for expression of progesrone receptor (PgR), Tau, ki67, HER2, Bcl-2 by immunohistochemistry (IHC), these data were used to test whether these biomarkers can predict tumor response. The primary endpoint was a pathologically complete response (pCR). The second endpoint was the change in tumor size between pre and post NCT.
Results
Univariate analysis showed that HER2 positive (53.85% vs 8.62%, p
Conclusions
This study investigates the value of traditional biological markers, Bcl-2 and Tau in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT.
Clinical trial identification
NCT02059876
Legal entity responsible for the study
N/A
Funding
Guangdong General Hospital
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract